Literature DB >> 1614964

Intestinal absorption of peptides and peptide analogues: implications of fasting pancreatic serine protease levels and pH on the extent of oral absorption in dogs and humans.

P J Sinko1.   

Abstract

In order to describe and predict the impact of intestinal metabolism on peptide absorption, intestinal chymotrypsin activity, flow rate, and pH were characterized in fasted, duodenally fistulated dogs as a function of gastrointestinal (GI) motility phase. GI motility was classified as either active or quiescent. Cumulative volume, F(t), and volumetric flow rate, Q(t), curves were constructed and the data were sorted according to motility phase. The mean +/- SE active phase pH was 6.4 +/- 0.3, whereas the quiescent phase pH was 7.3 +/- 0.3. The difference between the mean active and the mean quiescent phase pH values was significant. The active and quiescent phase flow rates (ml/min) were also significantly different, at values of 1.2 +/- 0.2 and 0.28 +/- 0.07, respectively. The active phase flow rates were consistent among the dogs studied; however, the quiescent phase flow rates were highly variable among the dogs. The variability of the quiescent phase flow rates was expected since phase II of the GI motility cycle is characterized by intermediate, irregular spike activity. The mean active and quiescent phase chymotrypsin activities were 1.87 x 10(-5) +/- 0.53 x 10(-5) and 1.56 x 10(-5) +/- 0.65 x 10(-5) M, respectively. The active phase values were not statistically different among dogs, however, the quiescent phase values were found to be highly variable among dogs. The difference between the active and the quiescent phase chymotrypsin mean levels, however, was not statistically significant. The chymotrypsin levels determined in dogs were found to be approximately 10 times greater than those reported in humans.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1614964     DOI: 10.1023/a:1015830600227

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  13 in total

1.  A modified spectrophotometric determination of chymotrypsin, trypsin, and thrombin.

Authors:  B C HUMMEL
Journal:  Can J Biochem Physiol       Date:  1959-12

2.  The substrate specificity and sedimentation behavior of delta-chymotrypsin.

Authors:  G W SCHWERT; S KAUFMAN
Journal:  J Biol Chem       Date:  1949-09       Impact factor: 5.157

3.  Distribution and fate of pancreatic enzymes in small intestine of the rat.

Authors:  D PELOT; M I GROSSMAN
Journal:  Am J Physiol       Date:  1962-02

4.  The stereospecificity of alpha-chymotrypsin.

Authors:  D W Ingles; J R Knowles
Journal:  Biochem J       Date:  1968-07       Impact factor: 3.857

5.  Upper gastrointestinal (GI) pH in young, healthy men and women.

Authors:  J B Dressman; R R Berardi; L C Dermentzoglou; T L Russell; S P Schmaltz; J L Barnett; K M Jarvenpaa
Journal:  Pharm Res       Date:  1990-07       Impact factor: 4.200

6.  A new, highly sensitive and specific assay for chymotrypsin.

Authors:  H Rinderknecht; R M Fleming
Journal:  Clin Chim Acta       Date:  1975-03-10       Impact factor: 3.786

7.  Enteropeptidase levels in duodenal juice of normal subjects and patients with gastrointestinal disease.

Authors:  H Rinderknecht; M R Nagaraja; N F Adham
Journal:  Am J Dig Dis       Date:  1978-04

8.  Gastric emptying of nondigestible solids in dogs: a hydrodynamic correlation.

Authors:  P J Sirois; G L Amidon; J H Meyer; J Doty; J B Dressman
Journal:  Am J Physiol       Date:  1990-01

9.  Comparison of gastrointestinal pH in dogs and humans: implications on the use of the beagle dog as a model for oral absorption in humans.

Authors:  C Y Lui; G L Amidon; R R Berardi; D Fleisher; C Youngberg; J B Dressman
Journal:  J Pharm Sci       Date:  1986-03       Impact factor: 3.534

10.  Effect of size and density on canine gastric emptying of nondigestible solids.

Authors:  J H Meyer; J Dressman; A Fink; G Amidon
Journal:  Gastroenterology       Date:  1985-10       Impact factor: 22.682

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.